CRO Fortrea 'disputes the accuracy' of Acelyrin's claims about immunology drug trial conduct
After Acelyrin said that a contract research organization and its vendor made “clinical trial execution errors” in a study of the biotech’s lead immunology treatment candidate, the CRO has responded and is pushing back against some of the claims.
North Carolina-based Fortrea, a large, decades-old CRO that recently spun out of Labcorp, said in an SEC filing on Wednesday that it “disputes the accuracy of statements that ACELYRIN has made and the characterization of those statements in subsequent media reports.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.